Amicus Therapeutics (FOLD) Misses Q2 EPS by 7c

August 9, 2016 7:55 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Amicus Therapeutics (NASDAQ: FOLD) reported Q2 EPS of ($0.40), $0.07 worse than the analyst estimate of ($0.33).

2016 Financial Guidance

Cash, cash equivalents, and marketable securities totaled $214.2 million at June 30, 2016. The Company’s balance sheet was strengthened during the second quarter of 2016 with $57.8 million in net proceeds under the existing at-the-marketing (ATM) financing facility and an additional $30 million in debt under an existing debt facility. Following the second quarter close, the Company raised an additional $39.3 million in net proceeds through the ATM facility and has raised the full $100 million allotted for the ATM facility. The Company expects to remain within the original 2016 net cash spend guidance of between $135 million and $155 million.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities


Add Your Comment